Valentina Prevolnik Rupel1, Marko Divjak2, Zsombor Zrubka3,4, Fanni Rencz3,5, László Gulácsi3, Dominik Golicki6, Dagmara Mirowska-Guzel6, Judit Simon7, Valentin Brodszky3, Petra Baji3, Jakub Závada8, Guenka Petrova9, Alexandru Rotar10, Márta Péntek3. 1. Institute for Economic Research, Kardeljeva ploščad 17, 1000, Ljubljana, Slovenia. rupelv@ier.si. 2. DOBA Business School, Prešernova ulica 1, 2000, Maribor, Slovenia. 3. Department of Health Economics, Corvinus University of Budapest, Fővám tér 8., H-1093, Budapest, Hungary. 4. Doctoral School of Management, Corvinus University of Budapest, Fővám tér 8., Budapest, 1093, Hungary. 5. Premium Postdoctoral Research Programme, Hungarian Academy of Sciences, Nádor u. 7, Budapest, 1051, Hungary. 6. Department of Experimental and Clinical Pharmacology, Center for Preclinical Research and Technology, Medical University of Warsaw, Poland, ul. Banacha 1b, 02-097, Warsaw, Poland. 7. Department of Health Economics, Centre for Public Health, Medical University of Vienna, Kinderspitalgasse 15/1, Vienna, 1090, Austria. 8. Institute of Rheumatology, Na Slupi 4, 128 00, Prague, Czech Republic. 9. Department of Social Pharmacy and Pharmacoeconomics, Faculty of Pharmacy, Medical University, Sofia, Bulgaria. 10. Department of Social Medicine, University of Amsterdam, Meibergdreef 9, 22660, 1100 DD, Amsterdam, The Netherlands.
Abstract
BACKROUND: Guidelines for economic analyses of health care technologies require local input data for reimbursement decisions in the countries of Central and Eastern Europe (CEE). The aim of this study was to systematically review and analyse the available empirical studies using the EQ-5D instrument as a measure of the health-related quality of life (HRQoL) in patients with neurological diseases. METHODS: A systematic literature search was performed up to 1st April 2018 to identify relevant studies in eight selected CEE countries. Original articles reporting on studies of neurological diseases using the EQ-5D instrument were analysed. RESULTS: Thirty-six articles, describing the results of 38 samples of patients and a total of 13,005 patients were included in the review. Most studies were from Hungary (44.4%) and none from Romania or Slovakia. EQ-5D utility scores were reported in 33 (91.7%) articles. In multiple sclerosis (MS) being the most represented disease, the average utility scores ranged from 0.49 in Austria to 0.80 in Poland with a weighted average of 0.69. EQ VAS scores for MS ranged from 39 in Czech Republic to 72.0 in Poland, with weighted average of 59.1. MS patients, together with epilepsy and essential tremor patients, estimated their HRQoL among the highest. CONCLUSIONS: EQ-5D research activity in neurology has been increasing through the years in studied CEE countries. There are clinical areas with the significant social burden, such as a migraine or meningitis, that are completely lacking data, other areas, such as stroke or epilepsy, with very scarce data.
BACKROUND: Guidelines for economic analyses of health care technologies require local input data for reimbursement decisions in the countries of Central and Eastern Europe (CEE). The aim of this study was to systematically review and analyse the available empirical studies using the EQ-5D instrument as a measure of the health-related quality of life (HRQoL) in patients with neurological diseases. METHODS: A systematic literature search was performed up to 1st April 2018 to identify relevant studies in eight selected CEE countries. Original articles reporting on studies of neurological diseases using the EQ-5D instrument were analysed. RESULTS: Thirty-six articles, describing the results of 38 samples of patients and a total of 13,005 patients were included in the review. Most studies were from Hungary (44.4%) and none from Romania or Slovakia. EQ-5D utility scores were reported in 33 (91.7%) articles. In multiple sclerosis (MS) being the most represented disease, the average utility scores ranged from 0.49 in Austria to 0.80 in Poland with a weighted average of 0.69. EQ VAS scores for MS ranged from 39 in Czech Republic to 72.0 in Poland, with weighted average of 59.1. MS patients, together with epilepsy and essential tremor patients, estimated their HRQoL among the highest. CONCLUSIONS: EQ-5D research activity in neurology has been increasing through the years in studied CEE countries. There are clinical areas with the significant social burden, such as a migraine or meningitis, that are completely lacking data, other areas, such as stroke or epilepsy, with very scarce data.
Entities:
Keywords:
Central and Eastern European countries; EQ-5D; Health-related quality of life; Neurological diseases
Authors: Mihály Herceg; Ferenc Nagy; Endre Pál; József Janszky; Ildikó Késmárky; Sámuel Komoly; Norbert Kovács Journal: Clin Neuropharmacol Date: 2012 Mar-Apr Impact factor: 1.592
Authors: Gisela Kobelt; Jenny Berg; Peter Lindgren; Carlotta Plesnilla; Ulf Baumhackl; Thomas Berger; Harald Kolleger; Karl Vass Journal: Eur J Health Econ Date: 2006-09
Authors: Yaroslav Winter; Sonja von Campenhausen; Julia Gasser; Klaus Seppi; Jens-P Reese; Karl-P Pfeiffer; Kai Bötzel; Wolfgang H Oertel; Richard Dodel; Werner Poewe Journal: J Neurol Date: 2009-11-28 Impact factor: 4.849